Introduction {#s1}
============

Glycated hemoglobin A~1c~ (HbA~1c~) is formed through a nonenzymatic reaction between glucose and hemoglobin. After formation, HbA~1c~ remains and accumulates primarily in erythrocytes throughout its life span. The blood level of HbA~1c~ reflects the average blood glucose level over ∼90 days. Genome-wide association studies (GWAS) have identified variants at multiple loci that are associated with HbA~1c~. In several instances, the presence of these variants is associated with altered glucose homeostasis, e.g., variants in or near solute carrier family 30 (zinc transporter); member 8 (S*LC30A8*) ([@B1]); transcription factor 7-like 2 (*TCF7L2*) ([@B2]); glucose-6-phosphatase, catalytic, 2 (*G6PC2*); glucokinase (*GCK*); melatonin receptor 1B (*MTNR1B*) ([@B3]); and CDK5 regulatory subunit associated protein 1-like 1 (*CDKAL1*) ([@B4]). Thus GWAS of HbA~1c~ may uncover variants that are relevant to the regulation of blood glucose or to the pathogenesis of type 2 diabetes (T2D) and complement GWAS for other glycemic traits.

HbA~1c~ is also affected by pathways that are not associated with the regulation of blood glucose. For example, in addition to the associations with HbA~1c~, several variants close to hemochromatosis (*HFE*); transmembrane protease, serine 6 (*TMPRSS6*); ATPase, class VI, type 11A/tubulin, γ-complex-associated protein 3 (*ATP11A*/*TUBGCP3*); ankyrin 1, erythrocytic (*ANK1*); spectrin, α, erythrocytic 1 (*SPTA1*); and hexokinase 1 (*HK1*) also showed suggestive or definitive associations with erythrocyte parameters ([@B5]--[@B10]). Several of these genes were also known to harbor rare variants that cause hereditary anemias ([@B11]--[@B13]). These raise the possibility that the impact of these variants on HbA~1c~ relates to their effects on erythrocyte half-life. Alternatively, variants near fructosamine 3 kinase (*FN3K*) may act through their effects on protein deglycation ([@B14]). These effects become particularly relevant now in that HbA~1c~ has been adopted as a diagnosis criterion of diabetes, because it exhibits less intraindividual variability than either fasting glucose or 2-h post challenge glucose after an oral glucose tolerance test and does not require fasting ([@B15],[@B16]). It is recognized that the glucose and HbA~1c~ criteria are not completely concordant and that genetic variants result in a significant reclassification of individuals based on HbA~1c~ criteria when compared with fasting glucose criteria ([@B17]).

To date, with one exception ([@B4]), all GWAS for HbA~1c~ have been conducted in populations of European ancestry. We have already demonstrated that genetic association studies in different ethnic groups offer opportunities to identify novel loci that harbor variants encoding susceptibility to T2D ([@B18],[@B19]). Furthermore, some hereditary anemias are more common in Asians, which may also affect HbA~1c~ ([@B20]). In this study, we sought to find common genetic variants at novel loci that are associated with blood HbA~1c~ level in the consortium of the Asian Genetic Epidemiology Network (AGEN; <http://www.agenconsortium.org/>), which consists of East Asian cohorts.

Research Design and Methods {#s2}
===========================

We conducted a meta-analysis of data from 16 cohorts comprising 32,602 individuals of East Asian ancestry ([Table 1](#T1){ref-type="table"}). The study was carried out in two stages. Stage 1 involved the meta-analysis of GWAS of 19,017 Chinese, Korean, Japanese, and Malay individuals, as well as an in silico lookup of all index single nucleotide polymorphisms (SNPs) with *P* value \<10^−4^ and their proxies (in total 198 SNPs) in 2,009 subjects of Chinese ancestry of the Singapore Chinese Health Study (SCHS) of diabetes. This gave a sample size of 21,026 for the discovery stage. In stage 2, we selected five genome-wide significant (*P* value ≤5 × 10^−8^) SNPs at potential novel loci from stage 1 and two SNPs that reached suggestive levels of significance at the fatty acid desaturase 2 (*FADS2*) and proteasome (prosome, macropain) 26S subunit, non-ATPase, 13 (*PSMD13*) genes in view of their known impact on blood lipid levels ([@B21]) and hematologic traits ([@B22]). We then carried out de novo genotyping of these SNPs in 9,592 Japanese individuals. In addition, 48 out of these 198 index SNPs were also genotyped in a study of 1,984 Chinese individuals of the TaiChi study. The findings from all these studies were then meta-analyzed.

###### 

Demographics of the participant cohorts

  Study name      *n*      Design         Ethnicity   Age, mean (SD)   Male, %   BMI, mean (SD)   HbA~1c~     λ~GC~      
  --------------- -------- -------------- ----------- ---------------- --------- ---------------- ----------- ---------- -------
  Stage 1         21,026                                                                          5.7 (0.6)   39 (6.6)   
   CRC            640      Population     Chinese     43.9 (7.7)       24.7      22.4 (2.2)       5.5 (0.4)   37 (4.4)   1.020
   KARE           7,696    Population     Korean      51.6 (8.8)       46.6      24.5 (3.8)       5.6 (0.4)   38 (4.4)   1.052
   CAGE-NCGM      323      Population     Japanese    63.0 (6.1)       53.6      22.9 (2.9)       5.2 (0.3)   33 (3.3)   1.001
   NHAPC          2,507    Population     Chinese     58.5 (6.0)       42.4      24.3 (3.6)       5.7 (0.4)   39 (4.4)   1.005
   SCES           1,580    Population     Chinese     57.7 (9.4)       42.2      23.5 (3.5)       5.8 (0.3)   40 (3.3)   1.002
   SiMES          1,727    Population     Malay       57.6 (11.2)      33.9      25.8 (5.1)       5.7 (0.4)   39 (4.4)   1.007
   SP2--610       797      Population     Chinese     47.4 (10.6)      17.0      22.2 (3.7)       5.6 (0.4)   38 (4.4)   1.027
   SP2--1M        777      Population     Chinese     46.7 (10.1)      61.5      22.8 (3.4)       5.6 (0.4)   38 (4.4)   1.006
   SP2--550       266      Population     Chinese     48.3 (12.2)      66.0      23.3 (3.5)       5.6 (0.4)   38 (4.4)   0.992
   TWSC           920      Population     Chinese     50.0 (17.8)      50.8      23.6 (3.5)       5.2 (0.4)   33 (4.4)   1.010
   SCHS-CHD       1,024    MI controls    Chinese     60.1 (8.0)       67.6      22.9 (3.1)       5.7 (0.4)   39 (4.4)   0.998
                  457      MI cases       Chinese     59.8 (7.8)       63.0      22.6 (2.9)       5.7 (0.4)   39 (4.4)   1.008
   SBCS           303      BC controls    Chinese     53.0 (8.4)       0.0       24.7 (5.1)       5.8 (0.4)   40 (4.4)   1.012
   SCHS-DB        2,009    T2D controls   Chinese     55.2 (7.1)       46.7      22.7 (3.1)       5.5 (0.3)   37 (3.3)   ---
  Stage 2         11,576                                                                                                 
   TaiChi         1,984    Population     Chinese     68.6 (9.0)       49.7      24.3 (3.4)       5.8 (0.3)   40 (3.3)   1.09
   CAGE-Fukuoka   4,880    Population     Japanese    63.8 (5.8)       46.2      22.7 (2.7)       4.8 (0.2)   29 (2.2)   NA
   JMGP           4,712    Population     Japanese    59.5 (14.3)      35.6      22.8 (3.1)       5.5 (0.4)   37 (4.4)   NA

The participant cohorts are listed in stage 1 (genome-wide association test) and stage 2 (de novo genotyping), respectively. Age, BMI, and HbA~1c~ are given as the mean value and SE in each cohort. λ~GC~ is the inflation factor calculated as per genomic control. CAGE, Cardiovascular Genomic Epidemiology; CRC, Cardiometabolic Risk in Chinese; JMGP, Japanese Millenium Genome Project; KARE, Korea Association Resource; NCGM, National Center for Global Health and Medicine; NHAPC, Nutrition and Health of Aging Population in China; SBCS, Shanghai Breast Cancer Study; SCES, Singapore Chinese Eye Study; SCHS-CHD, Singapore Chinese Health Study of Coronary Heart Disease; SCHS-DB, Singapore Chinese Health Study of Diabetes Mellitus; SiMES, Singapore Malay Eye Study; SP2, Singapore Progressive Study Program; TWSC, Taiwan Super Control Study.

^1^The International Federation of Clinical Chemistry unit for HbA~1c~ is mmol/mol.

Most of the studies were population-based cross-sectional studies in adults. For the studies that used a case-control design to study genetic association with diabetes, only nondiabetic control individuals were included in this study. For other case-control studies, the association testing was done in cases and controls separately. The average HbA~1c~ across the participating studies varied between 4.8 and 5.8%, while the SDs were less than 0.4%. All subjects provided written informed consent. Detailed information of each study can be found in [Table 1](#T1){ref-type="table"} and the [Supplementary Data](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1815/-/DC1).

SNP Genotyping, Quality Control, and Imputation {#s3}
-----------------------------------------------

Our stage 1 cohorts were genotyped on Affymetrix (Santa Clara, CA) and Illumina SNP arrays. We applied stringent sample and SNP quality control (QC) within each study separately. As a result, the QC criteria varied slightly across these studies, but the following steps have been largely applied ([Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1815/-/DC1)). Firstly, we excluded samples that showed cryptic relatedness, were population outliers, or showed inconsistency between clinical and genetic genders. Secondly, we removed SNPs with minor allele frequency (MAF) \<1%, genotype call rate \<0.95, or Hardy-Weinberg equilibrium *P* value ≤1 × 10^−6^.

We imputed our post-QC array genotypes up to the HapMap phase 2 haplotypes ([@B23]) using several widely used software packages. For the cohorts of Chinese, Korean, and Japanese ancestry, HapMap haplotypes of the Japanese in Tokyo, Japan (JPT) and Chinese in Beijing, China (CHB) were used as the reference panel in the imputation. For Malays, the combined African Yoruba in Ibadan, Nigeria (YRI); Utah residents with ancestry from Northern and Western Europe (CEU); and JPT+CHB panels were used. The combined HapMap panel resulted in about 1.9 million SNPs in the imputed genotypes, while there were 2.4 million in the imputation data when the JPT+CHB panel was used. Imputed SNPs of MAF \<1%, Hardy-Weinberg equilibrium *P* value ≤1 × 10^−6^, or poor imputation quality (IMPUTE info \<0.5, BEAGLE allelic *R*^2^ \<0.5, or MACH *R*~sq~ \<0.3) were removed ([@B24]--[@B26]).

In stage 2, the follow-up SNPs were genotyped on three platforms. The two Japanese cohorts were genotyped using the TaqMan system (Life Technologies Corporation, Carlsbad, CA). The TaiChi cohort was genotyped using the Illumina Cardio-MetaboChip (San Diego, CA). The same SNP QC criteria as in stage 1 were applied to the two Japanese studies, while similar sample QC and SNP QC as in stage 1 were applied to TaiChi study ([Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1815/-/DC1)).

Phenotype Definition {#s4}
--------------------

The traditional HbA~1c~ unit (percentage of HbA~1c~ in total hemoglobin) was used in the analysis. Subjects with diabetes were excluded. Diabetes was diagnosed if the subject gave a history of physician-diagnosed diabetes, was taking medication for diabetes, or had fasting glucose ≥7 mmol/L or HbA~1c~ ≥6.5% (48 mmol/mol) in those studies where fasting glucose was not available. The HbA~1c~ measurements were fitted into a linear model that adjusted for the sex and BMI of the individuals. The residuals were then normalized to have a mean of 0 and an SD of 1 using inverse-normal transformation.

Association With HbA~1c~ and Meta-analysis {#s5}
------------------------------------------

We tested the association of the SNPs with the normalized HbA~1c~ residuals using linear regression assuming additive effects of the dosage of the effect allele. The linear regression was evaluated by several widely used software packages ([Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1815/-/DC1)). Study-specific covariates, such as principal components and sample recruitment sites, were also considered as required ([Supplementary Data](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1815/-/DC1)).

The results from separate studies were combined using the fixed-effect scheme weighted by the inverse of the SE as implemented in METAL ([@B27]). Genomic control was applied within METAL.

Results {#s6}
=======

In total, we identified nine loci harboring variants associated with HbA~1c~ levels in East Asian populations. Among them, four loci were associated with HbA~1c~ for the first time. The fixed-effect meta-analysis showed no significant evidence of heterogeneity for most of the index SNPs in the cohorts we have recruited. Although the heterogeneity test for variants near the *G6PC2/*ATP-binding cassette, subfamily B (MDR/TAP), member 11 (*ABCB11*) locus reached a borderline level of statistical significance, the extent of heterogeneity was moderate ([Supplementary Table 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1815/-/DC1)).

Known Associated Loci Replicated in East Asian Populations {#s7}
----------------------------------------------------------

In stage 1, the maximal inflation factor was 1.052 in the Korea Association Resource (KARE) study, while those of the other studies were all ∼1, indicating that population stratification was unlikely to confound our findings ([Table 1](#T1){ref-type="table"}). [Supplementary Fig. 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1815/-/DC1) shows the quantile--quantile plots with and without the SNPs known to be associated with HbA~1c~. This displayed a marked deviation from the null hypothesis of no association that persisted after all known SNPs associated with HbA~1c~ were removed. In this stage, we had ∼81% power to discover genomic variants that explain 0.2% phenotype variance at a significance level of *P* = 5× 10^−8^.

The associations between index SNPs at novel and known loci are presented in [Table 2](#T2){ref-type="table"}. Ten loci showed associations with HbA~1c~ with *P* values that met the criteria for genome-wide significance (*P* value ≤5 × 10^−8^) ([Fig. 1](#F1){ref-type="fig"}). Of these, five were at loci that were known to harbor variants associated with HbA~1c~ levels. The index SNPs at these known loci were rs7772603 in the *CDKAL1* gene region, rs3755157 at the *G6PC2/ABCB11* locus, rs1799884 near the *GCK* gene, rs4737009 in the *ANK1* gene region, and rs1046875 near the *FN3K* gene. We investigated the linkage disequilibrium (LD) between our top SNPs, and the reported index SNPs at these loci identified in populations of European ancestry ([Supplementary Table 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1815/-/DC1)). At the *GCK* and *FN3K* loci, our index SNPs were exactly the same as or were in perfect LD with the index SNPs reported in Europeans. In fact, the SNP identified in populations of European ancestry at both loci (rs1046896 near the *FN3K* locus and rs730497 near the *GCK* locus) ([@B3]) also showed genome-wide significant associations in our meta-analysis (*P* value = 3.4 × 10^−13^ and 1.3 × 10^−18^ after genomic control). For *ANK1*, we replicated the primary signal rs4737009 reported in populations of European ancestry (*P* value = 1.3 × 10^−15^) ([@B3]). This same study identified a second variant (rs6474359) in the *ANK1* region, which was not in LD with the primary signal at this locus. This second SNP showed only a minor association with HbA~1c~ in our study (*P* value = 9.3 × 10^−3^), with an opposite direction of effect compared with Europeans.

###### 

Association of the top hits of stage 1 and stage 2 in East Asians

  SNP                                           Gene           Chr   Base pair position   Alleles   Stage   Risk allele frequency   Effect (SE)   *P* value   *n*
  --------------------------------------------- -------------- ----- -------------------- --------- ------- ----------------------- ------------- ----------- --------
  Novel loci                                                                                                                                                  
   rs6684514[\*](#t2n1){ref-type="table-fn"}    TMEM79         1     154,522,080          G/A       1       0.75                    0.09 (0.01)   1.1E-15     20,831
                                                                                                    2       0.78                    0.09 (0.02)   2.1E-09     9,494
                                                                                                    1+2     0.76                    0.09 (0.01)   1.3E-23     30,325
   rs9399137[\*](#t2n1){ref-type="table-fn"}    HBS1L/MYB      6     135,460,711          T/C       1       0.72                    0.06 (0.01)   1.9E-08     20,535
                                                                                                    2       0.65                    0.07 (0.01)   7.6E-08     9,501
                                                                                                    1+2     0.69                    0.07 (0.01)   8.5E-15     30,036
   rs1467311                                    9q31.2         9     109,576,753          G/A       1       0.22                    0.07 (0.01)   2.9E-08     20,845
                                                                                                    2       0.24                    0.01 (0.01)   3.5E-01     11,474
                                                                                                    1+2     0.23                    0.04 (0.01)   1.0E-06     32,319
   rs540078                                     PSMD13         11    244,256              T/C       1       0.46                    0.04 (0.01)   6.2E-06     20,865
                                                                                                    2       0.39                    0.01 (0.01)   4.1E-01     9,485
                                                                                                    1+2     0.44                    0.03 (0.01)   3.2E-05     30,350
   rs174570                                     FADS2          11    61,353,788           C/T       1       0.52                    0.05 (0.01)   5.4E-07     20,639
                                                                                                    2       0.59                    0.03 (0.01)   3.8E-02     11,524
                                                                                                    1+2     0.55                    0.04 (0.01)   2.0E-07     32,163
   rs9933309[\*](#t2n1){ref-type="table-fn"}    CYBA           16    87,372,433           C/T       1       0.64                    0.08 (0.01)   3.3E-08     11,015
                                                                                                    2       0.63                    0.05 (0.03)   1.1E-01     1,983
                                                                                                    1+2     0.63                    0.07 (0.01)   1.1E-08     12,998
   rs11667918[\*](#t2n1){ref-type="table-fn"}   MYO9B          19    17,093,499           C/T       1       0.61                    0.06 (0.01)   1.9E-10     20,835
                                                                                                    2       0.65                    0.04 (0.01)   3.7E-03     9,516
                                                                                                    1+2     0.62                    0.06 (0.01)   9.0E-12     30,351
  Known loci                                                                                                                                                  
   rs3755157[\*](#t2n1){ref-type="table-fn"}    G6PC2/ABCB11   2     169,500,417          T/C       1       0.34                    0.07 (0.01)   2.8E-11     20,630
   rs7772603[\*](#t2n1){ref-type="table-fn"}    CDKAL1         6     20,773,925           C/T       1       0.42                    0.06 (0.01)   3.5E-08     19,156
   rs1799884[\*](#t2n1){ref-type="table-fn"}    GCK            7     44,195,593           T/C       1       0.19                    0.12 (0.01)   1.5E-22     20,874
   rs4737009[\*](#t2n1){ref-type="table-fn"}    ANK1           8     41,749,562           A/G       1       0.50                    0.09 (0.01)   1.3E-15     20,558
                                                                                                    2       0.54                    0.05 (0.03)   1.4E-01     1,984
                                                                                                    1+2     0.51                    0.08 (0.01)   1.1E-15     22,542
   rs1046875[\*](#t2n1){ref-type="table-fn"}    FN3K           17    78,278,715           A/G       1       0.49                    0.08 (0.01)   1.6E-14     20,871
                                                                                                    2       0.52                    0.11 (0.03)   2.6E-04     1,984
                                                                                                    1+2     0.49                    0.08 (0.01)   3.8E-17     22,855

The index SNPs were grouped into novel loci that were first discovered in our study and known loci that have been reported in previous publications. Gene refers to the most relevant gene within each locus. The cytoband of 9q31.2 was designated to rs1467311 since no gene was found in the 400 Kb flanking region nearby. Alleles are given as the effect allele/other allele. Effect and SE are the risk and its SE, respectively. For the novel loci, association result were given for the stage 1, stage 2, and the meta-analyzed stage 1 and stage 2, indicated as 1, 2, and 1+2, respectively. Chr, chromosome number.

\*The index SNPs showed genome-wide significance in stage 1.

![Manhattan plot of genome-wide meta-analysis of stage 1 cohorts. The −log~10~ of the association *P* values (*y*-axis) are plotted against the genomic coordinates (*x*-axis). The horizontal line in the plot indicates the genome-wide significance (5 × 10^−8^). The most relevant gene of each signal was labeled on the top of it, with the novel loci presented in brown and known loci in blue.](2551fig1){#F1}

The index SNP identified in European populations at *G6PC2/ABCB11* (rs552976) did not show any association with HbA~1c~ in our meta-analysis (*P* value = 0.54). However, we did identify an association with rs3755157 near this locus that reached genome-wide significance. Although there was no evidence of LD between this and rs552976 in either HapMap panels of European (CEU) or Asian (JPT and CHB) ancestry ([Supplementary Table 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1815/-/DC1)), rs3755157 did show a genome-wide significant association with fasting glucose in populations of European ancestry ([Supplementary Tables 4 and 5](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1815/-/DC1)). We conducted association tests with and without conditioning on the European SNP rs552976 in Singapore cohorts, including 5,147 Chinese and Malays. *P* values for rs3755157 were 1.5 × 10^−4^ and 1.4 × 10^−4^ with and without conditioning on rs552976, respectively. In addition, the index SNP at the *CDKAL1* locus (rs7772603) was different from rs7747752 identified in the Korean cohort that formed part of this analysis. However, these two SNPs showed moderate LD in the JPT+CHB panel, and rs7747752 showed an association with HbA~1c~ that was in the same direction and similar magnitude as that reported previously in the Korean population ([@B4]), with a suggestive degree of statistical significance in our study (*P* value = 1.1 × 10^−5^). This suggests that associations with HbA~1c~ for these two variants may represent the same association signal.

We further compared the direction of the effect for known HbA~1c~-associated variants between European and East Asian populations ([Supplementary Table 6](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1815/-/DC1)). Of the 17 index SNPs associated with HbA~1c~ in previous publications, rs1800562 (*HFE*) is monomorphic in East Asians, while rs16926246 (*HK1*) was excluded because of the poor imputation quality. Most of the remaining 15 index SNPs showed consistent effects between Europeans and East Asians ([Fig. 2](#F2){ref-type="fig"}). The only exception was rs6474359 at the *ANK1* locus, for which each copy of the T allele was associated with higher HbA~1c~ level by 0.06% in Europeans (*P* value = 1.2 × 10^−8^) but lower HbA~1c~ level by 0.08 SD of the normalized HbA~1c~, which was equivalent to 0.05% HbA~1c~ (*P* value = 9.3 × 10^−3^), assuming a normal distribution of HbA~1c~ in our study.

![The bivariate plot of the effect directions in our meta-analysis and in previous reports. For the index SNPs in the previous GWAS, we plotted the reported effect (*x*-axis) versus the AGEN effect (*y*-axis). Whenever available, we used the effects reported by Soranzo et al. ([@B3]). The solid dots represent the SNPs that were significant (*P* value ≤0.05) in our study, while the hollow red dots represent the insignificant ones. The *CDKAL1* top SNP reported in Koreans was specially marked by a diamond. EA, East Asian.](2551fig2){#F2}

Novel Associated Loci Revealed in East Asian Populations {#s8}
--------------------------------------------------------

The other five genome-wide significant hits in stage 1 were all novel associations ([Table 2](#T2){ref-type="table"}). These five variants and two additional SNPs (rs540078 at *PSMD13* and rs174570 at *FADS2*) were examined in stage 2. Of these, data for the top SNP at cytochrome b-245, α polypeptide (*CYBA*; rs9933309) was available only in the TaiChi study, which consists of 1,984 Chinese. Four of these seven SNPs were replicated successfully in our stage 2 cohorts with consistent effect directions and showed stronger associations after combining the results of stage 2 and stage 1 with *P* values less than 5 × 10^−8^. They were variants close to the transmembrane protein 79 (*TMEM79*), Hsp70 subfamily B suppressor 1-like protein/v-myb avian myeloblastosis viral oncogene homolog (*HBS1L/MYB*), *CYBA*, and myosin IXB (*MYO9B*) loci ([Table 2](#T2){ref-type="table"}). The remaining SNPs, rs1467311 at 9q31.2 (stage 1+2 meta-analysis *P* value = 1.0 × 10^−6^), rs174570 in *FADS2* (*P* value = 2.0 × 10^−7^), and rs540078 in *PSMD13* (*P* value = 3.2 × 10^−5^) did not show genome-wide significant association with HbA~1c~ in stage 1 and stage 2 meta-analysis. The regional association signals at the novel loci and the known loci were presented in [Fig. 3](#F3){ref-type="fig"} and [Supplementary Fig. 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1815/-/DC1), respectively.

![Regional association plots of the novel loci. The −log~10~ of association *P* values are plotted against the genomic coordinates. The index SNPs are indicated in purple, with circles for stage 1 and squares for stage 1+2. Other SNPs are colored from red to blue as per their LD with the index SNP. Chr, chromosome.](2551fig3){#F3}

For the novel loci identified in East Asians, the MAF of the index SNPs in HapMap JPT+CHB panel were comparable to those in CEU panel ([Supplementary Table 7](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1815/-/DC1)). In most cases, the direction of effect was the same in AGEN as it was in the study of European ancestry, with the exception of rs6684514 at *TMEM79.* However, this SNP showed only a nominal degree of statistical significance in Europeans (*P* value = 4.0 × 10^−2^).

Association With Fasting Glucose and Erythrocyte Traits {#s9}
-------------------------------------------------------

We also looked up the associations between the variants that reached genome-wide significance with glucose-related traits in Europeans ([@B28]--[@B30]) and Asians ([@B19],[@B31]) ([Supplementary Tables 4 and 5](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1815/-/DC1)). SNPs near *GCK* and *G6PC2* were associated with blood glucose in both Europeans and East Asians. SNPs at the *CDKAL1* locus were associated with T2D in East Asians. Among the known loci, *FN3K* and *ANK1* were not associated with glucose level and T2D in either East Asians or Europeans. For the novel SNPs associated with HbA~1c~ that we identified in this study, none showed a statistically significant association with glucose levels except rs9399137 near the *HBS1L/MYB* loci, which showed an association with fasting glucose with borderline statistical significance that did not survive Bonferroni correction. We next examined the associations between these variants and red-cell-associated parameters in Europeans ([@B6],[@B8]) and East Asians ([@B32]) ([Supplementary Tables 8 and 9](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1815/-/DC1)). Variants close to *TMEM79*, *HBS1/MYB*, *CYBA*, and *ANK1* showed statistically significant associations with red-cell-associated parameters in at least one population.

Phenotype Variance Explained by the Associated Loci {#s10}
---------------------------------------------------

We estimated the phenotype variance explained (PVE) by the genome-wide significant index SNPs in our meta-analysis. The PVE in each cohort was calculated by fitting the raw HbA~1c~ in a linear regression model on the allele dosages of the index SNPs under investigation. The adjusted r-squared from the linear regression model was used as the estimation of PVE. The estimates were obtained for the novel, known loci and all loci separately. The estimates from separate studies were combined using a sample-size-weighted scheme.

In Singapore Chinese Eye Study (SCES), Singapore Malay Eye Study (SiMES), and the three Singapore Progressive Study Program (SP2) cohorts, the known loci and the novel loci explained 1.01% and 0.75% of the total HbA~1c~ variance, respectively, while all the index SNPs as a whole explained 1.76% HbA~1c~ variance.

Reclassification of Diabetes Diagnosis Using HbA~1c~ {#s11}
----------------------------------------------------

Finally, we calculated the proportion of the samples that were reclassified by adjusting for the allele dosage of index SNPs at the six loci that did not show association with glucose or T2D in populations of either European ancestry ([@B28]--[@B30]) or Asian ancestry ([@B19],[@B31]). These included *TMEM79*, *HBS1L*/*MYB*, *CYBA*, *MYO9B*, *ANK1*, and *FN3K*.

This reclassification analysis was done in 15,150 individuals with fasting glucose measurements available, which came from SP2, KARE, Nutrition and Health of Aging Population in China (NHAPC), National Center for Global Health and Medicine (NCGM), Cardiometabolic Risk in Chinese (CRC), and TaiChi. Individuals with known diabetes (defined by having diabetic history or using diabetic medication) were removed. In the remaining subjects, undiagnosed diabetes was defined as those having fasting glucose ≥7 mmol/L, whereas the nondiabetic individuals had fasting glucose \<7 mmol/L. We adjusted the raw HbA~1c~ levels using a linear regression, including the allele dosages of the six SNPs as covariates. We then classified individuals into those with and without diabetes based on HbA~1c~ ≥6.5% ([@B15]). We compared the concordance between these three methods for diagnosing diabetes (fasting glucose, HbA~1c~, and HbA~1c~ adjusted for these six SNPs) ([Table 3](#T3){ref-type="table"}).

###### 

Individual reclassification using raw HbA~1c~ or adjusted HbA~1c~

                               Adjusted HbA~1c~   Subtotal   Total    
  ---------------------------- ------------------ ---------- -------- --------
  Fasting plasma glucose ≥7                                           
   HbA~1c~ \<6.5               57                 1          58       181
   HbA~1c~ ≥6.5                3                  120        123      
  Fasting plasma glucose \<7                                          
   HbA~1c~ \<6.5               13,813             40         13,853   14,329
   HbA~1c~ ≥6.5                172                304        476      

The reclassification analysis was done in cohorts with fasting glucose measurement. Individuals with known diabetic history or diabetic medication were removed. In the remaining subjects, undiagnosed diabetes was defined as those having fasting glucose ≥7 mmol/L, whereas the nondiabetic individuals had fasting glucose \<7 mmol/L. We adjusted the raw HbA~1c~ levels using a linear regression, including the allele dosages of the six SNPs as covariates. We then classified individuals into those with and without diabetes based on HbA~1c~ ≥6.5% ([@B15]). We compared the concordance between these three methods for diagnosing diabetes (fasting glucose ≥7.0 mmol/L, HbA~1c~ ≥6.5%, and HbA~1c~ adjusted for these six SNPs ≥6.5%). HbA~1c~ was adjusted on the nonglycemic index SNPs. The subtotal is the number of individuals in each HbA~1c~ category. The reclassification rate in each HbA~1c~ category is the ratio of the number of individuals reclassified after adjustment for the six SNPs to the subtotal. The total is the number of individuals in each fasting plasma glucose category.

One hundred eighty-one subjects had undiagnosed diabetes based on fasting glucose, of which 123 had HbA~1c~ ≥6.5%, of whom three had adjusted HbA~1c~ \<6.5%. Fifty-eight individuals had HbA~1c~ \<6.5%, of which one had adjusted HbA~1c~ ≥6.5%.

In contrast, 14,96 individuals were nondiabetic, with fasting glucose \<7.0 mmol/L. Of these, 476 were classified as having diabetes based on HbA~1c~ ≥6.5%. However, 172 of the 476 individuals had adjusted HbA~1c~ \<6.5%; 14,493 had HbA~1c~ \<6.5%. Of these, 40 had adjusted HbA~1c~ ≥6.5%. As such, some nonconcordance was observed when diabetes was diagnosed based on fasting plasma glucose ≥7.0 mmol/L and HbA~1c~ ≥6.5%. Among those with fasting plasma glucose ≥7.0 mmol/L, very little of the nonconcordance was explained by these six variants. However, among those with fasting plasma glucose \<7.0 mmol/L, 36.13% of those with elevated HbA~1c~ had HbA~1c~ \<6.5% after these six variants were taken into consideration.

In populations of European ancestry, the equivalent proportion was 15.18% ([@B3]).

Discussion {#s12}
==========

In this East Asian GWAS meta-analysis, we showed that most of the variants identified in populations of European ancestry had similar effects in East Asians. Variants close to the *G6PC2/ABCA11*, *GCK*, *ANK1*, and *FN3K* that were first identified in populations of European ancestry also showed associations that reached genome-wide significance in our study. However, at the *G6PC2/ABCB11*, our index SNP was not in LD with the index SNP (rs552976) identified in populations of European ancestry. The latter was not associated with HbA~1c~ in our study (*P* value = 0.54). Therefore, rs3755157 could represent an additional signal at this locus, particularly given that we did not observe obvious attenuation of the associations in the analysis conditioning on rs552976. Another SNP at this locus (rs560887) was associated with fasting glucose in Europeans ([@B28]) but not with HbA~1c~ in our study (*P* value = 0.10). The majority of the other known SNPs showed similar direction of effect and effect size in our population as in populations of European Ancestry. The exception was a variant at the *ANK1* locus with showed an association in the opposite direction to that observed in populations of European ancestry. We are not able to explain this finding at this time. However, we would point out that the association in our study, although in a different direction, was far from reaching genome-wide significance. Larger sample sizes will be required to formally test for heterogeneity of effect of this variant in populations of European and East Asian ancestry.

We identified variants at or close to four novel loci associated with HbA~1c~ in this meta-analysis. *TMEM79* is a transmembrane protein that is highly expressed in liver, erythrocytes, and adipose tissue (The European Bioinformatics Institute, Expression Atlas database, <http://www.ebi.ac.uk/gxa>). The index SNP rs6684514 was also associated with mean corpuscular hemoglobin concentration in a GWAS conducted in Japanese ([@B32]). Although this suggests that this SNP may exert its effects in HbA~1c~ through its effects on erythrocyte biology, we cannot exclude the possibility that this variant could alter glucose regulation. *TMEM79* is downregulated by a high-fat diet in adipose tissue in mice ([@B33]). *TMEM79* is also differentially methylated in adipose tissue in twins discordant for T2D. However, this association did not survive multiple testing ([@B34]). The index SNP at the *TMEM79* locus rs6684514 was a common missense variant (Val147Met). However, this was predicted as benign by sorting intolerant from tolerant (SIFT) ([@B35]) and polymorphism phenotyping (PolyPhen) ([@B36]). We also looked for other functional variants in the nearby genes. Three missense SNPs were found to be in high LD (*r*^2^ = 0.97; MAF = 0.22) with rs6684514. They were rs10908495 and rs10908496 at the *C1orf85* locus and rs2230194 at the *CCT3* locus. However, their *P* values were all less than 3.7 × 10^−9^ in stage 1. Haplotype analysis showed that there were only two common haplotypes (frequency \>0.01) in Chinese cohorts of SCES and SP2. They were A-C-A-A and G-T-G-G for rs6684514-rs10908495-rs10908496-rs2230194, while G-T-G-G carried all the alleles associated with elevated HbA~1c~. Hence, we are unable to discriminate the genuine causal variant among these four missense variants. rs2230194 did not exist in the combined reference panel of HapMap CEU, JPT+CHB, and YRI and hence was absent in Malay cohort of SiMES.

The index SNP rs9399137 is located in the intergenic region between *HBS1L* and *MYB* genes and resides in a LD block (*HMIP 2*), which contains SNPs associated with various hematology traits ([@B5]--[@B8],[@B22],[@B37],[@B38]), including HbA~2~ ([@B39]) and HbF ([@B40]). Another SNP in the same LD block was associated with mean corpuscular hemoglobin, erythrocyte count, and other hematology traits significantly in the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium ([@B6]). The index SNPs reported by CHARGE were in moderate/high LD with rs9399137 (*r*^2^ ranges from 0.45 to 1.00 in HapMap release 22 CEU panel). This observation was also supported by recent GWAS in African Americans ([@B9],[@B41]). A study has shown a distal regulatory element may exist here to control the expression of *MYB* gene ([@B42]), which plays an important role in erythrocyte formation and differentiation.

*MYO9B* codes for a single-head myosin isoform that was found to be expressed primarily in peripheral blood white cells ([@B43]). The product of the gene is important for actin remodeling of epithelial enterocytes, hence it has been associated with several inflammatory bowel diseases, such as Crohn disease and celiac disease, in which the impairment of the enterocyte function explained part of the disease syndrome ([@B44]). *MYO9B* function could have an impact on both glycemic and nonglycemic determinants of HbA~1c~. Celiac disease can result in anemia ([@B45]) due to various nutrient deficiencies. This can alter red cell turnover and thus HbA~1c~ level. In addition, celiac disease is also associated with lower BMI and a lower prevalence of T2D ([@B46]). Actually, the T allele of our index SNP rs11667918 was associated with lower BMI in another meta-analysis conducted by AGEN (*P* value = 0.03) ([@B47]), as well as lower HbA~1c~ level in our study. Furthermore, intestinal permeability may have a role in the pathogenesis of type 1 diabetes (T1D) ([@B48]). *MYO9B*'s expression is altered by a hydrolyzed casein diet, which is also able to prevent diabetes in the DP-BB mouse, a mouse model of T1D ([@B49]). Variants at this locus showed an association with T1D in a Spanish population ([@B50]). However, this finding was not replicated in Dutch and British populations ([@B51]). Another SNP rs2279008 at *MYO9B* was associated with human height ([@B52]), which was weakly associated with T2D ([@B53]), but this SNP is not in LD with our index SNP rs11667918 in both CEU and JPT+CHB panels.

Although, the association of the index SNP of *CYBA* rs9933309 in our replication cohort was not statistically significant, this SNP was only genotyped in a small number of individuals as part of the replication cohorts due to limitations of resources. However, the association after meta-analysis did reach GWAS significance, and the same SNP showed an association with HbA~1c~ in the Meta-Analyses of Glucose and Insulin-Related Traits Consortium (MAGIC) meta-analysis ([@B3]), with an effect direction consistent with that found in our study and *P* value of 1.2 × 10^−4^ ([Supplementary Table 7](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1815/-/DC1)). For this reason, we believe that this variant is very likely to represent a true positive finding in our study. *CYBA* encodes p22phox, a subunit of NADPH oxidase. NADPH oxidase produces superoxide after catalyzing the reaction from NADPH to NADPH^+^. In phagocytes, these superoxides are released to kill bacteria and fungi. Since p22phox is the primary component of this microbicidal system, mutations in *CYBA* gene were reported to cause immunodeficiency diseases, such as the recessive chronic granulomatous disease ([@B54]). Of relevance to glucose metabolism, higher NADPH oxidase activity, together with higher levels of its subunits, including p22phox, was found to be induced by high environmental glucose in a T2D rat model ([@B55]). This increased oxidative stress has been observed in both animal ([@B56]) and human ([@B57]) β-cell models. In fact, the β-cell is particularly susceptible to the effects of oxidative stress because of the relatively lower expression level of superoxide dismutase, which is protective against oxidation damage, as compared with other tissues ([@B58]). It has been argued that high-glucose-induced superoxide was the major cause of β-cell dysfunction and death ([@B59]). Thus variants at the *CYBA* locus may result in oxidative stress in the β-cell, leading to glucose intolerance. However, this variant did not show any association with glycemic traits or T2D in any of the populations examined ([Supplementary Table 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1815/-/DC1)). Instead, it showed an association with mean cell hemoglobin concentration and mean corpuscular volume in Japanese population, as well as hemoglobin level in a population of European ancestry ([Supplementary Table 8 and 9](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1815/-/DC1)).

It is noteworthy that six of the nine variants that showed genome-wide significant associations with HbA~1c~ showed no evidence of association with glucose traits or T2D. This included three out of four of the variants at novel loci identified in our study (*TMEM79*, *HBS1L/MYB*, and *MYO9B*). Several of these showed strong associations with red-cell-associated parameters (*TMEM79*, *HBS1/MYB*, *ANK1*, and *CYBA*). Another (FNK3) is thought to influence HbA~1c~ by impacting the deglycation of proteins ([@B14]) rather than through an impact on glucose metabolism. Approximately 3.3% of the populations studied with fasting plasma glucose \<7.0 mmol/L would have been diagnosed as having diabetes based on HbA~1c~ ≥6.5%. Over one-third of this nonconcordance could be explained by these six variants. These findings may have implications for the diagnosis of diabetes using HbA~1c~ in East Asians. It may be that the threshold for diagnosing diabetes based on HbA~1c~ should be slightly higher in these populations. However, an evaluation of appropriate thresholds for the diagnosis of diabetes really requires a careful examination of the relationship between HbA~1c~ and microvascular complications associated with diabetes in these populations. Most of the studies included in this analysis did not have data on microvascular complications, and this is outside the scope of this study. These variants may also contribute to the observation that in individuals with diabetes, Southeast and East Asians exhibit HbA~1c~ that is ∼0.2--0.5% higher compared with Caucasians with similar mean blood glucose level ([@B60]).

In conclusion, common genetic variants associated with HbA~1c~ levels in populations of European ancestry have similar effects on HbA~1c~ levels in East Asians. We identified four novel associated genomic loci in our East Asian populations. Existing data point to an effect that is mediated by the effect of these variants on nonglycemic factors that affect the erythrocyte for at least three of these variants. However, we cannot conclusively exclude the possibility that they may have an impact on glucose regulation. These findings may have implication on the use of HbA~1c~ to diagnose diabetes in East Asian populations.
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###### Supplementary Data

This article contains Supplementary Data online at <http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1815/-/DC1>.
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